EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation

Ying Wang, Tianzi Wei, Man Zhao, Aima Huang, Fan Sun, Lu Chen, Risheng Lin, Yubao Xie, Ming Zhang, Shiyu Xu, Zhihui Sun, Liang Hong und 3 weitere

PLOS Biology · 2024

DOI: 10.1371/journal.pbio.3002550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2024. Verfasst von Ying Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases, Oxindoles, Cell Cycle Proteins. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Innovation and Development Project of Lanzhou University, CAMS Innovation Fund for Medical Sciences (CIFMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alkenyl oxindoles have been characterized as autophagosome-tethering compounds (ATTECs), which can target mutant huntingtin protein (mHTT) for lysosomal degradation. In order to expand the application of alkenyl oxindoles for targeted protein degradation, we designed and synthesized a series of heterobifunctional compounds by conjugating different alkenyl oxindoles with bromodomain-containing protein 4 (BRD4) inhibitor JQ1. Through structure-activity relationship study, we successfully developed JQ1-alkenyl oxindole conjugates that potently degrade BRD4. Unexpectedly, we found that these molecules degrade BRD4 through the ubiquitin-proteasome system, rather than the autophagy-lysosomal pathway. Using pooled CRISPR interference (CRISPRi) screening, we revealed that JQ1-alkenyl oxindole conjugates recruit the E3 ubiquitin ligase complex CRL4 DCAF11 for substrate degradation. Furthermore, we validated the most potent heterobifunctional molecule HL435 as a promising drug-like lead compound to exert antitumor activity both in vitro and in a mouse xenograft tumor model. Our research provides new employable proteolysis targeting chimera (PROTAC) moieties for targeted protein degradation, providing new possibilities for drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisUbiquitin-Protein LigasesOxindolesCell Cycle ProteinsHumansAnimalsMiceTranscription FactorsCell Line, TumorXenograft Model Antitumor AssaysMice, NudeHEK293 CellsStructure-Activity RelationshipProteasome Endopeptidase ComplexAzepinesAntineoplastic AgentsFemaleBromodomain Containing ProteinsReceptors, Interleukin-17

Substanzen

Ubiquitin-Protein LigasesOxindolesCell Cycle ProteinsTranscription FactorsProteasome Endopeptidase ComplexAzepinesAntineoplastic AgentsBromodomain Containing ProteinsReceptors, Interleukin-17BRD4 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
  • Key University Laboratory of Metabolism and Health of Guangdong, Department of Medical Neuroscience, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
  • Institute of Materia Medica and Research Unit of Peptide Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Guofeng Li

Förderung

  • National Natural Science Foundation of China
  • Medical Innovation and Development Project of Lanzhou University
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • the Medical Innovation and Development Project of Lanzhou University
  • the CAMS Innovation Fund for Medical Sciences
  • Guangdong Basic and Applied Basic Research Foundation
  • the Science, Technology and Innovation Commission of Shenzhen Municipality
  • the Lingang Laboratory Grant

Zitieren

APA

Wang, Y., Wei, T., Zhao, M., Huang, A., Sun, F., Chen, L., Lin, R., Xie, Y., Zhang, M., Xu, S., Sun, Z., Hong, L., Wang, R., Tian, R., & Li, G. (2024). Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002550

Vancouver

Wang Y, Wei T, Zhao M, Huang A, Sun F, Chen L, et al. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation. PLOS Biology. 2024. doi:10.1371/journal.pbio.3002550

BibTeX
@article{Wang2024,
  author = {Wang, Ying and Wei, Tianzi and Zhao, Man and Huang, Aima and Sun, Fan and Chen, Lu and Lin, Risheng and Xie, Yubao and Zhang, Ming and Xu, Shiyu and Sun, Zhihui and Hong, Liang and Wang, Rui and Tian, Ruilin and Li, Guofeng},
  title = {Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation},
  journal = {PLOS Biology},
  year = {2024},
  doi = {10.1371/journal.pbio.3002550}
}
Kostenlos starten →